Paul G. Richardson
Expertise in
18
conditions

Dr. Paul G. Richardson

Hematology Oncology | Oncology | Hematology
450 Brookline Avenue, 
Boston, MA 
Offers Telehealth
Expertise in
18
conditions
450 Brookline Avenue, 
Boston, MA 

Overview

Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Richardson is highly rated in 18 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 669 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of London, St. Bartholomew's Medical College, 1986

Residency

Newcastle General And Freeman Hospitals, 1990

Specialties

Hematology Oncology
Oncology
Hematology

Licenses

Internal Medicine in MA

Board Certifications

Medical Oncology

Fellowships

Baystate Medical Center, 1994

Hospital Affiliations

Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
450 Brookline Avenue, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 2
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Pomalidomide, Dexamethasone
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: EZM0414
Study Phase: Phase 1
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drugs: Melphalan Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 2
View 8 Less Clinical Trials

669 Total Publications

Utility of fluorinated α-amino acids in development of therapeutic peptides.
Utility of fluorinated α-amino acids in development of therapeutic peptides.
Journal: Expert opinion on drug discovery
Published: December 18, 2025
Similar Doctors
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
 (25.8 miles away)
617-632-2166
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Reardon is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Reardon is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy.

Richard M. Stone
Expertise in
34
conditions
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Expertise in
34
conditions
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Adult Leukemia Program

450 Brookline Avenue, 
Boston, MA 
 (25.8 miles away)
617-632-2214
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Stone is highly rated in 34 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Priscilla Merriam
Expertise in
31
conditions
Dr. Priscilla Merriam
Hematology Oncology | Hematology | Oncology
Expertise in
31
conditions
Dr. Priscilla Merriam
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Sarcoma And Bone Cancer Treatment Center

450 Brookline Avenue, 
Boston, MA 
 (25.8 miles away)
617-632-5204
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Priscilla Merriam is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Merriam is highly rated in 31 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, and Epithelioid Sarcoma.

Frequently Asked Questions about Dr. Paul G. Richardson

How do I make an appointment with Dr. Paul G. Richardson?

You can book an appointment with Dr. Paul G. Richardson by calling their office at 617-632-2104. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul G. Richardson a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul G. Richardson is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul G. Richardson specialize in?

While Dr. Paul G. Richardson is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, and Relapsed Refractory Multiple Myeloma (RRMM). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Paul G. Richardson participate in research or clinical trials?

Yes. Dr. Paul G. Richardson has published 669 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Paul G. Richardson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul G. Richardson accept my insurance?

Dr. Paul G. Richardson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-632-2104 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Richardson's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile